Free Trial

Amphastar Pharmaceuticals (AMPH) Competitors

Amphastar Pharmaceuticals logo
$22.60 -0.26 (-1.14%)
Closing price 07/8/2025 04:00 PM Eastern
Extended Trading
$22.60 +0.00 (+0.00%)
As of 04:05 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

AMPH vs. ADMA, PCVX, RYTM, CYTK, KRYS, AKRO, ZLAB, PTCT, RARE, and AAPG

Should you be buying Amphastar Pharmaceuticals stock or one of its competitors? The main competitors of Amphastar Pharmaceuticals include ADMA Biologics (ADMA), Vaxcyte (PCVX), Rhythm Pharmaceuticals (RYTM), Cytokinetics (CYTK), Krystal Biotech (KRYS), Akero Therapeutics (AKRO), Zai Lab (ZLAB), PTC Therapeutics (PTCT), Ultragenyx Pharmaceutical (RARE), and Ascentage Pharma Group International (AAPG). These companies are all part of the "pharmaceutical products" industry.

Amphastar Pharmaceuticals vs. Its Competitors

ADMA Biologics (NASDAQ:ADMA) and Amphastar Pharmaceuticals (NASDAQ:AMPH) are both medical companies, but which is the better stock? We will compare the two companies based on the strength of their institutional ownership, analyst recommendations, valuation, profitability, dividends, earnings, media sentiment and risk.

75.7% of ADMA Biologics shares are held by institutional investors. Comparatively, 65.1% of Amphastar Pharmaceuticals shares are held by institutional investors. 3.7% of ADMA Biologics shares are held by company insiders. Comparatively, 27.1% of Amphastar Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

ADMA Biologics has a beta of 0.43, meaning that its stock price is 57% less volatile than the S&P 500. Comparatively, Amphastar Pharmaceuticals has a beta of 0.72, meaning that its stock price is 28% less volatile than the S&P 500.

In the previous week, ADMA Biologics had 1 more articles in the media than Amphastar Pharmaceuticals. MarketBeat recorded 6 mentions for ADMA Biologics and 5 mentions for Amphastar Pharmaceuticals. ADMA Biologics' average media sentiment score of 1.27 beat Amphastar Pharmaceuticals' score of 0.23 indicating that ADMA Biologics is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
ADMA Biologics
4 Very Positive mention(s)
1 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Amphastar Pharmaceuticals
2 Very Positive mention(s)
1 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
1 Very Negative mention(s)
Neutral

ADMA Biologics presently has a consensus target price of $27.67, suggesting a potential upside of 55.34%. Amphastar Pharmaceuticals has a consensus target price of $32.33, suggesting a potential upside of 43.07%. Given ADMA Biologics' stronger consensus rating and higher possible upside, equities analysts plainly believe ADMA Biologics is more favorable than Amphastar Pharmaceuticals.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
ADMA Biologics
0 Sell rating(s)
0 Hold rating(s)
2 Buy rating(s)
1 Strong Buy rating(s)
3.33
Amphastar Pharmaceuticals
0 Sell rating(s)
3 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
2.25

ADMA Biologics has higher earnings, but lower revenue than Amphastar Pharmaceuticals. Amphastar Pharmaceuticals is trading at a lower price-to-earnings ratio than ADMA Biologics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
ADMA Biologics$426.45M9.97$197.67M$0.8520.95
Amphastar Pharmaceuticals$731.97M1.46$159.52M$2.768.19

ADMA Biologics has a net margin of 45.01% compared to Amphastar Pharmaceuticals' net margin of 19.38%. ADMA Biologics' return on equity of 47.16% beat Amphastar Pharmaceuticals' return on equity.

Company Net Margins Return on Equity Return on Assets
ADMA Biologics45.01% 47.16% 30.51%
Amphastar Pharmaceuticals 19.38%22.20%10.40%

Summary

ADMA Biologics beats Amphastar Pharmaceuticals on 13 of the 17 factors compared between the two stocks.

Get Amphastar Pharmaceuticals News Delivered to You Automatically

Sign up to receive the latest news and ratings for AMPH and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding AMPH and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

AMPH vs. The Competition

MetricAmphastar PharmaceuticalsMED IndustryMedical SectorNASDAQ Exchange
Market Cap$1.08B$3.90B$5.47B$8.95B
Dividend YieldN/A1.16%5.25%4.04%
P/E Ratio8.196.6126.9620.11
Price / Sales1.4611.11430.20119.79
Price / Cash4.576.5336.8257.86
Price / Book1.482.657.985.56
Net Income$159.52M-$109.62M$3.16B$248.40M
7 Day Performance-4.16%-2.03%2.39%4.67%
1 Month Performance-15.10%2.80%2.18%6.64%
1 Year Performance-38.90%25.82%33.82%21.31%

Amphastar Pharmaceuticals Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
AMPH
Amphastar Pharmaceuticals
4.4152 of 5 stars
$22.60
-1.1%
$32.33
+43.1%
-39.5%$1.08B$731.97M8.192,028
ADMA
ADMA Biologics
4.1301 of 5 stars
$17.88
-2.2%
$27.67
+54.7%
+53.0%$4.36B$426.45M21.04530Positive News
PCVX
Vaxcyte
1.5822 of 5 stars
$32.00
-3.8%
$136.50
+326.6%
-57.8%$4.29BN/A-8.02160
RYTM
Rhythm Pharmaceuticals
3.4426 of 5 stars
$66.39
+0.9%
$78.07
+17.6%
+48.9%$4.18B$130.13M-23.63140News Coverage
Analyst Forecast
CYTK
Cytokinetics
3.9048 of 5 stars
$33.36
-3.8%
$70.92
+112.6%
-39.6%$4.14B$18.47M-6.31250
KRYS
Krystal Biotech
4.4862 of 5 stars
$139.74
-2.3%
$211.13
+51.1%
-25.1%$4.13B$290.52M33.59210
AKRO
Akero Therapeutics
3.4454 of 5 stars
$51.52
-0.5%
$82.50
+60.1%
+127.0%$4.13BN/A-26.4230
ZLAB
Zai Lab
3.2563 of 5 stars
$35.48
-2.5%
$54.28
+53.0%
+105.9%$4.04B$398.99M-14.251,869
PTCT
PTC Therapeutics
4.2867 of 5 stars
$47.98
-2.2%
$65.00
+35.5%
+50.2%$3.89B$806.78M7.371,410
RARE
Ultragenyx Pharmaceutical
4.0595 of 5 stars
$39.61
-0.8%
$87.00
+119.6%
-5.0%$3.77B$560.23M-6.741,294
AAPG
Ascentage Pharma Group International
N/A$42.04
-1.9%
N/AN/A$3.73B$134.35M0.00600News Coverage
Positive News

Related Companies and Tools


This page (NASDAQ:AMPH) was last updated on 7/9/2025 by MarketBeat.com Staff
From Our Partners